Hologic (NASDAQ:HOLX – Get Free Report) released its earnings results on Monday. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04, Briefing.com reports. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the business earned $0.93 EPS. The business’s quarterly revenue was up 2.7% compared to the same quarter last year.
Hologic Stock Performance
Shares of NASDAQ:HOLX traded up $1.42 on Tuesday, reaching $81.06. 303,577 shares of the company’s stock were exchanged, compared to its average volume of 1,609,527. The company has a fifty day moving average of $74.66 and a 200-day moving average of $75.08. Hologic has a twelve month low of $64.02 and a twelve month high of $81.27. The company has a market capitalization of $18.92 billion, a price-to-earnings ratio of 41.36, a PEG ratio of 2.62 and a beta of 0.99. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52.
Insiders Place Their Bets
In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.
Wall Street Analysts Forecast Growth
About Hologic
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Read More
- Five stocks we like better than Hologic
- Learn Technical Analysis Skills to Master the Stock Market
- This Semiconductor Stock Is ON Track for a New High
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Why SoFi Stock is an Unmissable Growth Opportunity
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Has Micron’s Stock Drop Turned Into A Screaming Buy?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.